Is It Rejection – or Something Else? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Is It Rejection – or Something Else?

  • By

  • Jessica Allerton

  • November 17, 2026

  • 6 min

Share

  • 1

    Kidney biopsy and histology remain central to evaluating graft dysfunction, while molecular testing adds information about gene activity in sampled tissue.

  • 2

    Molecular results do not always establish the cause of injury and should be interpreted with histology, laboratory findings, and clinical history.

  • 3

    Creatinine changes can reflect rejection, infection, medication toxicity, reduced blood flow, obstruction, or recurrent disease, which may require different treatments.

  • 4

    Treating nonrejection injury as rejection by increasing immunosuppression could impair infection control, and immunosuppressive therapies carry other risks.

  • 5

    Blood- and urine-based biomarkers are under investigation for monitoring, but current evidence does not support using them as universal replacements for biopsy.

Original Source(s)

Related Content